GlassScriptPhysician profile
Elizabeth Ann Rutherford
NPI 1083653711
$2,397.92
in general payments reported to CMS, 2019-2025
25 companies · $15.89 in 2025
The $15.89 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $282 · 2021: $469 · 2022: $823 · 2023: $298 · 2025: $15.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.53 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Hologic Sales and Service, LLC | $231.49 | 2021-2022 | |
| Coopersurgical, INC. | $147.08 | 2019-2020 | |
| Astellas Pharma US INC | $118.60 | 2020-2023 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $114.57 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $80.86 | 2019 | |
| Avion Pharmaceuticals | $73.23 | 2019-2023 | Balcoltra |
| Pfizer INC. | $66.47 | 2019-2022 | |
| Agile Therapeutics, INC. | $65.53 | 2021-2023 | Twirla |
| Merck Sharp & Dohme LLC | $61.74 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $53.39 | 2022-2023 | |
| Myovant Sciences INC. | $51.60 | 2021-2022 | |
| Exeltis, USA INC. | $43.58 | 2020-2021 | |
| Novo Nordisk INC | $39.60 | 2022 | |
| Lupin INC. | $39.32 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $26.16 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.56 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.11 | 2022 | |
| Organogenesis INC. | $19.72 | 2021 | |
| Boston Scientific Corporation | $18.31 | 2019 | |
| Medicem INC. | $17.93 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.40 | 2021 | |
| Hologic INC | $14.20 | 2021 | |
| Dysis Medical, INC. | $12.26 | 2021 | |
| Aspira Women'S Health INC | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Rutherford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.